Key Findings: Early Surgery Linked to Improved Asthma Control

The core finding of the retrospective study is that early intervention with ESS—defined as surgery performed within six months of a CRSwNP diagnosis—was associated with a demonstrably lower incidence of moderate and severe persistent asthma over a five-year follow-up period. Specifically, patients in the early surgery cohort exhibited significantly reduced odds of developing moderate persistent asthma (odds ratio [OR] 0.84, P=0.012) and severe persistent asthma (OR 0.76, P=0.003) compared to those who had their surgery delayed for one to three years.

Furthermore, the benefits extended to asthma exacerbations, with early ESS patients experiencing fewer severe asthma attacks during the follow-up (OR 0.78, P=0.005). This reduction in asthma-related events could translate into fewer emergency room visits, hospitalizations, and overall diminished quality of life impacts for individuals managing both conditions.

The study also highlighted a notable difference in medication utilization. Patients undergoing early ESS showed a decreased need for several classes of asthma medications. This included lower rates of long-acting beta-agonists (LABAs) (23.7% versus 29.4%, OR 0.75, P<0.001), systemic corticosteroids (63.7% versus 67.4%, OR 0.85, P=0.0009), and advanced biologic therapies (7.7% versus 10.1%, OR 0.74, P=0.0004). The reduced reliance on these treatments underscores the potential for early surgical intervention to mitigate the overall burden of asthma management.

Beyond clinical outcomes and medication use, the study observed a trend towards lower absolute eosinophil counts in the early ESS group (372 versus 618 cells/µL, P=0.04). Eosinophils are a type of white blood cell that plays a significant role in allergic inflammation and is often elevated in individuals with severe asthma and CRSwNP. A decrease in these counts may suggest a more effectively controlled inflammatory cascade.

Understanding the Link Between CRSwNP and Asthma

The interconnectedness of the upper and lower airways has long been recognized by medical professionals. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory condition affecting the nasal passages and sinuses, often characterized by the presence of nasal polyps. Asthma, a chronic inflammatory disease of the airways, frequently coexists with CRSwNP. Estimates suggest that up to 70-80% of patients with CRSwNP also have asthma, and conversely, a substantial proportion of individuals with asthma experience sinonasal symptoms.

This comorbidity is not merely coincidental. The inflammatory processes driving CRSwNP are believed to contribute to or exacerbate asthma. Nasal polyps can obstruct airflow, increase mucus production, and harbor chronic inflammation that may spill over into the lower respiratory tract. This continuous inflammatory cycle can make asthma more difficult to control, leading to increased symptom severity, more frequent exacerbations, and a greater need for medication, including potent corticosteroids and biologics.

Endoscopic sinus surgery (ESS) is a well-established treatment for CRSwNP, aiming to clear blockages, improve sinus drainage, and reduce inflammation in the sinonasal cavities. Previous research has demonstrated that ESS can lead to improvements in asthma-related symptoms, enhance patients’ quality of life, and decrease their medication requirements. However, the specific impact of the timing of ESS on long-term asthma morbidity had remained an area requiring further investigation.

Study Design: A Large-Scale Retrospective Analysis

To address this knowledge gap, researchers embarked on a retrospective propensity score-matched cohort study, leveraging the extensive data within the TriNetX Research Network. This network is a global federated electronic health record research platform that aggregates de-identified data from over 107 healthcare organizations, encompassing more than 100 million patient records. Such a large and diverse dataset allows for robust statistical analysis and the identification of trends that might not be apparent in smaller, localized studies.

The study identified adult patients diagnosed with CRSwNP who subsequently underwent ESS. These patients were then categorized into two distinct groups based on the timing of their surgery relative to their diagnosis:

  • Early Surgery Cohort: Patients who underwent ESS within six months of their CRSwNP diagnosis.
  • Delayed Surgery Cohort: Patients who underwent ESS between one to three years after their CRSwNP diagnosis.

To ensure a clear distinction between the groups and to minimize confounding factors related to intermediate timing, patients who received surgery between six and twelve months after diagnosis were excluded from the analysis. This design aimed to create two clearly defined cohorts with potentially different trajectories of disease management and outcomes.

The study focused on assessing asthma-related outcomes over an extended five-year follow-up period. Propensity score matching was a crucial methodological step. This statistical technique was employed to balance the baseline characteristics of the two cohorts, such as demographics, the severity of their asthma at the time of diagnosis, and their initial use of asthma medications. By matching patients based on these critical factors, researchers aimed to reduce the likelihood that observed differences in outcomes were due to pre-existing disparities between the groups rather than the timing of surgery itself.

Methodology and Data Analysis

The initial identification process within the TriNetX network yielded a substantial number of patients: 27,519 individuals in the early ESS group and 3,928 in the delayed ESS group. Following the rigorous propensity score matching process, the study was able to create two equally sized cohorts of 3,683 patients each. This matching ensured that, on average, patients in both the early and delayed surgery groups had similar baseline profiles regarding age, sex, comorbidities, asthma severity metrics, and medication use prior to their surgery. The average follow-up duration for both matched cohorts was approximately 3.6 years, providing a substantial window to observe long-term trends.

The researchers meticulously analyzed several key outcome measures. The incidence of new asthma diagnoses was a primary endpoint, with no significant difference observed between the early (10.8%) and delayed (10.9%) surgery groups (OR 0.99, P=0.89). This finding suggests that the timing of ESS did not influence the initial development of asthma in patients with CRSwNP, but rather its subsequent control and severity.

The critical findings related to persistent asthma severity and exacerbations were derived from analyzing electronic health record data, which typically includes physician diagnoses, medication orders, and clinical notes. The reduction in moderate persistent asthma (11.5% in early vs. 13.5% in delayed) and severe persistent asthma (6.5% in early vs. 8.4% in delayed) was statistically significant, indicating a tangible benefit of earlier surgical intervention. Similarly, the lower rate of asthma exacerbations in the early surgery group (6.4% vs. 8.1%) points to improved disease stability.

Medication utilization data, also extracted from the electronic health records, provided further quantitative evidence of the impact of surgical timing. The observed decreases in the use of LABAs, corticosteroids, and biologics in the early ESS cohort align with the notion of better-controlled asthma, as these medications are typically employed when asthma is not adequately managed with simpler therapies.

Absolute eosinophil counts, a biomarker for eosinophilic inflammation, were also analyzed. The significantly lower final recorded counts in the early ESS group suggest a potential reduction in the underlying inflammatory processes that contribute to both CRSwNP and asthma severity.

Implications and Future Directions

The findings of this study have significant implications for clinical practice and patient management. For individuals diagnosed with CRSwNP, particularly those with coexisting asthma, the timing of surgical intervention may emerge as a critical factor in optimizing long-term health outcomes. The data suggests that delaying ESS beyond six months after diagnosis might be associated with a higher risk of developing more severe and persistent asthma, leading to increased treatment complexity and potentially greater morbidity.

This research provides a robust, albeit retrospective, evidence base that can inform shared decision-making between clinicians and patients. When discussing treatment options for CRSwNP, particularly in patients with asthma, the potential benefits of timely ESS in managing both upper and lower airway inflammation could be emphasized.

However, the authors and independent commentators acknowledge the inherent limitations of retrospective studies. Potential residual confounding factors—variables that were not fully captured or balanced by propensity score matching—could still influence the results. The absence of pulmonary function testing and validated asthma control scores in the dataset means that direct objective measures of lung function and asthma control beyond medication use and exacerbation events could not be fully assessed. Furthermore, distinguishing between the use of corticosteroids and biologics for treating CRSwNP versus asthma was not possible, as these medications can be used for both conditions. Detailed metrics of CRSwNP severity, such as Lund-Mackay scores (a standardized grading system for sinus opacification), were also not available.

Despite these limitations, the study’s large sample size and rigorous methodology lend considerable weight to its conclusions. The observed trends are compelling and warrant further prospective investigation to confirm these findings and explore the underlying biological mechanisms. Future research could involve randomized controlled trials that directly compare early versus delayed ESS in CRSwNP patients with asthma, incorporating detailed assessments of lung function, inflammatory markers, and validated quality-of-life questionnaires.

Expert Commentary and Clinical Context

Dr. Ashoke Khanwalkar, a medical professional providing commentary on the study, underscored the significance of the findings in the context of existing knowledge. "While the impact of CRSwNP on asthma control is well-established, and ESS can improve asthma control and outcomes, this study looks further into the timing of ESS for CRSwNP in relation to future asthma control," Dr. Khanwalkar stated. He emphasized that the study’s retrospective database evaluation provides "further support when counseling patients on the role of surgery to control their inflammatory disease—not just whether to proceed with surgery, but also a timeframe."

This perspective highlights the practical utility of the research. It moves beyond the simple question of whether surgery is beneficial to addressing a more nuanced aspect of its application: optimizing the timing for maximum patient benefit. The findings suggest that a proactive approach to surgical intervention for CRSwNP in asthmatic patients may yield significant long-term advantages in managing their lower airway disease.

The publication is cited as: Oliver JR, et al. Asthma outcomes following early versus delayed sinus surgery in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2026;16:477-483. doi:10.1002/alr.70091. This reference allows medical professionals and researchers to access the original study for detailed examination.

In conclusion, this comprehensive analysis of real-world data from the TriNetX network offers valuable insights into the critical role of surgical timing in managing the complex interplay between CRSwNP and asthma. The evidence presented suggests that earlier endoscopic sinus surgery is associated with a more favorable long-term asthma trajectory, potentially reducing disease severity, exacerbations, and the need for aggressive medical management. While further prospective studies are needed to solidify these findings, the current research provides a strong foundation for reconsidering the optimal timing of ESS in this patient population.